Rating Change
Cantor Fitzgerald analysts initiated coverage on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) with a rating of Overweight on October 15, 2026.
new coverageOTC:ELOX
Cantor Fitzgerald Initiates Coverage on Eloxx Pharmaceuticals, Inc. (ELOX) with Overweight
Cantor Fitzgerald analysts initiated coverage on Eloxx Pharmaceuticals, Inc. (OTC:ELOX) with a rating of Overweight on October 15, 2026.
At publication ·
What changed
Eloxx Pharmaceuticals, Inc. (OTC:ELOX) · new coverage
- Firm
- Cantor Fitzgerald
- Rating
- Overweight
- Price at event
- $13.70
- Market capitalization
- $314.0
At a glance
Key takeaways
- Cantor Fitzgerald initiated Overweight coverage on Eloxx Pharmaceuticals (ELOX) on October 15, 2026, as the stock trades at $13.70 with a $314.0 million market capitalization.
Market Context
Eloxx Pharmaceuticals, Inc. operates in the Healthcare sector. The stock currently trades at $13.70 with a market capitalization of 314.0. The stock has gained 12699900.0% over the past 52 weeks.
Analyst coverage from Cantor Fitzgerald provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Eloxx Pharmaceuticals, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Eloxx Pharmaceuticals, Inc.
Among the 10 most recent ratings: 9 Buy, 1 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 15, 2026 | Cantor Fitzgerald | Overweight | N/A |
| Sep 18, 2026 | Leerink Partners | Outperform | N/A |
| Aug 24, 2026 | Guggenheim | Buy | N/A |
| Aug 20, 2026 | LUCID CAPITAL MARKETS | Buy | N/A |
| Jul 22, 2026 | LifeSci Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ELOX Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ELOX?
A rating of Overweight from Cantor Fitzgerald reflects the analyst's outlook on Eloxx Pharmaceuticals, Inc. (OTC:ELOX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ELOX forecast page.
